About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zentalis Pharmaceuticals, Inc. - common stock (NQ:ZNTL)

4.085 +0.085 (+2.12%)
Streaming Delayed Price Updated: 12:24 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zentalis Pharmaceuticals, Inc. - common stock

News headline image
Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
From Newman Ferrara LLP
Via Business Wire
News headline image
Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
News headline image
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)
From Newman Ferrara LLP
Via Business Wire
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30... 
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.